{"id":"https://openalex.org/W7225612350","doi":"https://doi.org/10.3389/fonc.2026.1944265","title":"Integrative bioinformatics and drug response profiling identify MEK/ERK inhibition as a strategy to overcome venetoclax resistance in AML","display_name":"Integrative bioinformatics and drug response profiling identify MEK/ERK inhibition as a strategy to overcome venetoclax resistance in AML","publication_year":2026,"publication_date":"2026-11-09","ids":{"openalex":"https://openalex.org/W7225612350","doi":"https://doi.org/10.3389/fonc.2026.1944265"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2026.1944265","doi":"https://doi.org/10.3389/fonc.2026.1944265","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1944265","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1944265/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1944265/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051804209","display_name":"Abeer A. Ogailan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I185163786","display_name":"King Abdulaziz University","ror":"https://ror.org/02ma4wv74","country_code":"SA","type":"education","lineage":["https://openalex.org/I185163786"]}],"countries":["SA"],"is_corresponding":false,"raw_author_name":"Abeer A. Al-Ogailan","raw_affiliation_strings":["Department of Biochemistry, Faculty of Science, King Abdulaziz University","Institute of Genomic Medicine Sciences, King Abdulaziz University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemistry, Faculty of Science, King Abdulaziz University","institution_ids":["https://openalex.org/I185163786"]},{"raw_affiliation_string":"Institute of Genomic Medicine Sciences, King Abdulaziz University","institution_ids":["https://openalex.org/I185163786"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003960456","display_name":"Sherin Bakhashab","orcid":"https://orcid.org/0000-0003-1580-0409","observed_orcids":["https://orcid.org/0000-0003-1580-0409"]},"institutions":[{"id":"https://openalex.org/I185163786","display_name":"King Abdulaziz University","ror":"https://ror.org/02ma4wv74","country_code":"SA","type":"education","lineage":["https://openalex.org/I185163786"]}],"countries":["SA"],"is_corresponding":false,"raw_author_name":"Sherin Bakhashab","raw_affiliation_strings":["Department of Biochemistry, Faculty of Science, King Abdulaziz University","Institute of Genomic Medicine Sciences, King Abdulaziz University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemistry, Faculty of Science, King Abdulaziz University","institution_ids":["https://openalex.org/I185163786"]},{"raw_affiliation_string":"Institute of Genomic Medicine Sciences, King Abdulaziz University","institution_ids":["https://openalex.org/I185163786"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010063085","display_name":"Abdul Ali Peer Zada","orcid":"https://orcid.org/0000-0002-9172-712X","observed_orcids":["https://orcid.org/0000-0002-9172-712X"]},"institutions":[{"id":"https://openalex.org/I2801911633","display_name":"King Fahd Medical City","ror":"https://ror.org/01jgj2p89","country_code":"SA","type":"healthcare","lineage":["https://openalex.org/I2801911633"]}],"countries":["SA"],"is_corresponding":false,"raw_author_name":"Abdul Ali Peer-Zada","raw_affiliation_strings":["Molecular Pathology Section, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Pathology Section, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City","institution_ids":["https://openalex.org/I2801911633"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017313075","display_name":"Farid Ahmed","orcid":"https://orcid.org/0000-0002-7464-7726","observed_orcids":["https://orcid.org/0000-0002-7464-7726"]},"institutions":[{"id":"https://openalex.org/I185163786","display_name":"King Abdulaziz University","ror":"https://ror.org/02ma4wv74","country_code":"SA","type":"education","lineage":["https://openalex.org/I185163786"]}],"countries":["SA"],"is_corresponding":true,"raw_author_name":"Farid Ahmed","raw_affiliation_strings":["Institute of Genomic Medicine Sciences, King Abdulaziz University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Genomic Medicine Sciences, King Abdulaziz University","institution_ids":["https://openalex.org/I185163786"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5017313075"],"corresponding_institution_ids":["https://openalex.org/I185163786"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9779999852180481},{"id":"https://openalex.org/keywords/venetoclax-resistance","display_name":"venetoclax resistance","score":0.9869999885559082},{"id":"https://openalex.org/keywords/mek-erk-inhibition","display_name":"MEK/ERK inhibition","score":0.8970000147819519},{"id":"https://openalex.org/keywords/erk-signaling","display_name":"ERK signaling","score":0.7570000290870667},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8579999804496765},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.8529999852180481},{"id":"https://openalex.org/keywords/mv4-11-cells","display_name":"MV4-11 cells","score":0.8880000114440918},{"id":"https://openalex.org/keywords/sorafenib-resistance","display_name":"sorafenib resistance","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hub-genes","display_name":"hub genes","score":0.7630000114440918},{"id":"https://openalex.org/keywords/protein-protein-interaction-network","display_name":"protein-protein interaction network","score":0.781000018119812},{"id":"https://openalex.org/keywords/selumetinib","display_name":"selumetinib","score":0.949999988079071},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.8420000076293945},{"id":"https://openalex.org/keywords/pp242","display_name":"PP242","score":0.9350000023841858},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.7829999923706055},{"id":"https://openalex.org/keywords/g0-g1-cell-cycle-arrest","display_name":"G0/G1 cell cycle arrest","score":0.8299999833106995},{"id":"https://openalex.org/keywords/transcriptional-reprogramming","display_name":"transcriptional reprogramming","score":0.7580000162124634}],"concepts":[{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6209999918937683},{"id":"https://openalex.org/C77255625","wikidata":"https://www.wikidata.org/wiki/Q402093","display_name":"Reprogramming","level":3,"score":0.5462999939918518},{"id":"https://openalex.org/C2776087337","wikidata":"https://www.wikidata.org/wiki/Q7448840","display_name":"Selumetinib","level":5,"score":0.527400016784668},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.5031999945640564},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.5012000203132629},{"id":"https://openalex.org/C18431079","wikidata":"https://www.wikidata.org/wiki/Q1502169","display_name":"Gene expression profiling","level":4,"score":0.4778999984264374},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4575999975204468},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.4481000006198883},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4438000023365021},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4415000081062317},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.439300000667572},{"id":"https://openalex.org/C55105296","wikidata":"https://www.wikidata.org/wiki/Q841382","display_name":"Interaction network","level":3,"score":0.4390999972820282},{"id":"https://openalex.org/C67339327","wikidata":"https://www.wikidata.org/wiki/Q1502576","display_name":"Gene regulatory network","level":4,"score":0.41339999437332153},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.3953999876976013},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3684000074863434},{"id":"https://openalex.org/C53811970","wikidata":"https://www.wikidata.org/wiki/Q5062194","display_name":"Centrality","level":2,"score":0.3580000102519989},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.353300005197525},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.35179999470710754},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.33880001306533813},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.3359000086784363},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3292999863624573},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.3287999927997589},{"id":"https://openalex.org/C162317418","wikidata":"https://www.wikidata.org/wiki/Q252857","display_name":"Transcriptome","level":4,"score":0.3285999894142151},{"id":"https://openalex.org/C28225019","wikidata":"https://www.wikidata.org/wiki/Q4915005","display_name":"Biological network","level":2,"score":0.3154999911785126},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3122999966144562},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3070000112056732},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.3059000074863434},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.28690001368522644},{"id":"https://openalex.org/C74401373","wikidata":"https://www.wikidata.org/wiki/Q1829843","display_name":"Bromodomain","level":4,"score":0.28529998660087585},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.27799999713897705},{"id":"https://openalex.org/C165864922","wikidata":"https://www.wikidata.org/wiki/Q411391","display_name":"Regulation of gene expression","level":3,"score":0.2732999920845032},{"id":"https://openalex.org/C71472368","wikidata":"https://www.wikidata.org/wiki/Q676880","display_name":"Text mining","level":2,"score":0.2680000066757202},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.2660999894142151},{"id":"https://openalex.org/C2780862049","wikidata":"https://www.wikidata.org/wiki/Q25326844","display_name":"BET inhibitor","level":5,"score":0.2644999921321869},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.26249998807907104},{"id":"https://openalex.org/C9927688","wikidata":"https://www.wikidata.org/wiki/Q4915012","display_name":"Biological pathway","level":4,"score":0.2563000023365021},{"id":"https://openalex.org/C41091548","wikidata":"https://www.wikidata.org/wiki/Q26939","display_name":"Epigenetics","level":3,"score":0.25189998745918274}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3389/fonc.2026.1944265","doi":"https://doi.org/10.3389/fonc.2026.1944265","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1944265","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1944265/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2026.1944265","doi":"https://doi.org/10.3389/fonc.2026.1944265","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1944265","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1944265/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320322322","display_name":"King Abdulaziz University","ror":"https://ror.org/02ma4wv74"},{"id":"https://openalex.org/F4320327296","display_name":"Ministry of Education \u2013 Kingdom of Saudi Arabi","ror":"https://ror.org/00q919b81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225612350.pdf","grobid_xml":"https://content.openalex.org/works/W7225612350.grobid-xml"},"referenced_works_count":43,"referenced_works":["https://openalex.org/W1967685674","https://openalex.org/W1967913221","https://openalex.org/W1974182237","https://openalex.org/W1977193433","https://openalex.org/W2016318120","https://openalex.org/W2017746705","https://openalex.org/W2037574296","https://openalex.org/W2077945404","https://openalex.org/W2096439168","https://openalex.org/W2101590448","https://openalex.org/W2165392081","https://openalex.org/W2535405120","https://openalex.org/W2588473985","https://openalex.org/W2606620588","https://openalex.org/W2810696819","https://openalex.org/W2945831681","https://openalex.org/W2946259536","https://openalex.org/W2984401723","https://openalex.org/W3069119239","https://openalex.org/W3099283460","https://openalex.org/W3116843665","https://openalex.org/W3133528596","https://openalex.org/W3157907580","https://openalex.org/W3201062596","https://openalex.org/W3206831592","https://openalex.org/W3210394811","https://openalex.org/W4212787271","https://openalex.org/W4214545722","https://openalex.org/W4223524932","https://openalex.org/W4285728223","https://openalex.org/W4307841122","https://openalex.org/W4312032753","https://openalex.org/W4323352072","https://openalex.org/W4400369422","https://openalex.org/W4403908292","https://openalex.org/W4403920876","https://openalex.org/W4404814472","https://openalex.org/W4407179350","https://openalex.org/W4410426199","https://openalex.org/W4412791006","https://openalex.org/W4412938418","https://openalex.org/W4414662805","https://openalex.org/W7160524770"],"related_works":["https://openalex.org/W4391517959","https://openalex.org/W4362543548","https://openalex.org/W3181622613","https://openalex.org/W3081612699","https://openalex.org/W3097474812","https://openalex.org/W4405039763","https://openalex.org/W4385702726","https://openalex.org/W4212787271","https://openalex.org/W4417010191","https://openalex.org/W4380029941"],"abstract_inverted_index":{"Background":[0],"Drug":[1],"resistance":[2,52,149,290,317],"remains":[3],"a":[4,66,152,169,255,294,304],"key":[5],"barrier":[6],"to":[7,26,156,215,236,314],"durable":[8],"remission":[9],"in":[10,71,274,287,318],"acute":[11],"myeloid":[12],"leukemia":[13],"(AML).":[14],"A":[15],"central":[16],"but":[17],"poorly":[18],"resolved":[19],"question":[20],"is":[21],"whether":[22,37],"AML":[23],"cells":[24,231],"resistant":[25,275],"mechanistically":[27],"distinct":[28,128],"drugs":[29],"converge":[30,292],"on":[31,95,205,293],"shared":[32,96,144,166],"downstream":[33],"survival":[34,297],"dependencies,":[35],"and":[36,65,89,108,172,190,263,309],"those":[38],"dependencies":[39],"can":[40],"be":[41],"exploited":[42],"therapeutically.":[43],"Methods":[44],"We":[45],"compared":[46],"transcriptional":[47],"reprogramming":[48],"across":[49,84,145,194],"3":[50],"independent":[51,196,211],"models":[53],"derived":[54],"from":[55,176],"the":[56,104,113,120,127,206,224,300],"FLT3-ITD-positive":[57],"MV4-11":[58,283],"cell":[59],"line:":[60],"midostaurin-resistant":[61],"cells,":[62,64,241,284],"sorafenib-resistant":[63],"novel":[67],"venetoclax-resistant":[68,230],"line":[69],"generated":[70],"our":[72],"laboratory.":[73],"Differential":[74],"expression":[75,138],"analysis,":[76,81],"protein":[77],"-protein":[78,160],"interaction":[79,161],"network":[80,86,162,197],"hub-gene":[82],"prioritization":[83],"multiple":[85,195,210],"centrality":[87,198],"algorithms,":[88],"pathway":[90,302],"enrichment":[91,201],"analyses":[92,202],"were":[93,117,232],"performed":[94,102],"upregulated":[97,142],"genes.":[98],"Functional":[99,221],"validation":[100,222],"was":[101],"using":[103,119,223],"MEK":[105,225,262],"inhibitor":[106,115,226],"selumetinib,":[107],"drug":[109,133],"combination":[110,122,312],"effects":[111],"with":[112,151,209,242,270],"mTOR":[114,264],"PP242":[116],"quantified":[118],"Chou-Talalay":[121],"index":[123],"method.":[124],"Results":[125],"Despite":[126],"mechanisms":[129],"through":[130],"which":[131,177],"each":[132],"exerts":[134],"its":[135],"effect,":[136],"differential":[137],"analysis":[139,163],"identified":[140],"328":[141],"genes":[143,167],"at":[146],"least":[147],"2":[148],"conditions,":[150],"meaningful":[153],"subset":[154],"common":[155],"all":[157],"3.":[158],"Protein":[159],"of":[164,218],"these":[165,279],"revealed":[168,228],"statistically":[170],"non-random":[171],"functionally":[173],"cohesive":[174],"network,":[175],"10":[178],"hub":[179],"genes:":[180],"TLR4,":[181],"PECAM1,":[182],"CYBB,":[183],"CXCL8,":[184],"CASP8,":[185],"ICAM1,":[186],"CD33,":[187],"CCL5,":[188],"CD36,":[189],"JUN,":[191],"emerged":[192],"consistently":[193],"algorithms.":[199],"Pathway":[200],"converged":[203],"prominently":[204],"MAPK/ERK":[207],"cascade,":[208],"terms":[212],"pointing":[213],"specifically":[214],"positive":[216],"regulation":[217],"ERK1/2":[219],"signaling.":[220],"selumetinib":[227],"that":[229,282],"modestly":[233],"more":[234],"sensitive":[235],"MAPK":[237,301],"inhibition":[238,265],"than":[239,252,258],"parental":[240],"growth":[243],"suppression":[244],"driven":[245],"predominantly":[246],"by":[247],"G0/G1":[248],"cell-cycle":[249],"arrest":[250],"rather":[251,257],"apoptosis,":[253],"indicating":[254],"cytostatic":[256],"cytotoxic":[259],"mechanism.":[260],"Combined":[261],"produced":[266],"synergistic":[267],"antiproliferative":[268],"effects,":[269],"greater":[271],"synergy":[272],"observed":[273],"cells.":[276],"Conclusion":[277],"Collectively,":[278],"findings":[280],"suggest":[281],"despite":[285],"diverging":[286],"their":[288],"proximal":[289],"mechanisms,":[291],"conserved":[295],"ERK-mediated":[296],"program,":[298],"positioning":[299],"as":[303],"broadly":[305],"relevant":[306],"therapeutic":[307],"vulnerability":[308],"supporting":[310],"MEK-based":[311],"strategies":[313],"overcome":[315],"acquired":[316],"AML.":[319]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-10T00:00:00"}